VVUS: VIVUS INC. (NASDAQ) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
VVUS: VIVUS INC. (NASDAQ)

An SI Board Since September 1997

Posts	SubjectMarks	Bans	Symbol
23519	69	0	VVUS

Emcee: Frostman	Type: Unmoderated

Introduction Market Data Compact

Vivus, Inc.: VVUS (NASDAQ)

WWW.VIVUS.COM

About VIVUS

VIVUS, Inc. is a pharmaceutical company engaged in the development
of innovative therapies for the treatment of quality-of-life disorders
in men and women, with a focus on sexual dysfunction. Current
development programs target Female Sexual Dysfunction (FSD), Erectile
Dysfunction (ED) and Premature Ejaculation (PE). The Company developed
and markets in the U.S. MUSE(R) (alprostadil) and ACTIS(R), two
innovations in the treatment of erectile dysfunction.

For further information: WWW.VIVUS.COM

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
23519	I like how their target of $6/share is over 100% above the stock's price but	The Ox	-	1/23/2015
23518	Thanks for the post. Ya, I do respect shorts, they usually do their homework. B	fred hayes	-	1/23/2015
23517	I think the main reason is the size of the short position. I just don't und	The Ox	-	1/23/2015
23516	LOL, you and me both....	mopgcw	-	1/22/2015
23515	Hang in there, I just don't understand how it could be this low. Had about	fred hayes	-	1/22/2015
23514	But hey, RBC initiated coverage on Vivus with an Outperform rating, I got that g	mopgcw	-	1/22/2015
23513	it is very unloved. unfortunately I still have more than enough shares, so no n	mopgcw	-	1/22/2015
23512	VVUS back to the level it was in March 2009. Looks like a strong buy but the mo	The Ox	-	1/22/2015
23511	they just are not generating the buzz with the prescriptions. the ED expansion	mopgcw	-	9/18/2014
23510	CS: Assuming Coverage - Maintain Neutral Koon Ching is assuming primary cover	mopgcw	-	9/18/2014
23509	Hard to imagine how this company continues to languish, with approved drugs in t	tom pope	-	9/18/2014
23508	VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA finance.yahoo.com	Julius Wong	-	9/18/2014
23507	That's probably the limit of what they figure they can get out of their bank	tom pope	-	5/28/2014
23506	seekingalpha.com	The Ox	-	5/28/2014
23505	That's only about $6.25 per share. A nice premium over today's stock pr	The Ox	-	5/28/2014
23504	<i>Aspen Investment Fund LLC is considering a nonbinding offer worth $640	tom pope	-	5/28/2014
23503	Turning into the gang that couldn't shoot straight. <i>	tom pope	-	5/6/2014
23502	Not necessarily the area I was hoping for, but it's had a mild favorable imp	tom pope	-	12/12/2013
23501	cs: VVUS disclosed that an estimated 108,000 Qsymia prescriptions were dispens	mopgcw	-	10/17/2013
23500	Vivus shares slip following analyst downgrade 2:31 PM 10/16/2013 - AcquireMedia	mopgcw	-	10/16/2013
23499	Thank you both!	tom pope	-	10/11/2013
23498	<Is there anything to differentiate Stendra from the incumbents?> Based o	Biotech Jim	-	10/11/2013
23497	Much faster...	fred hayes	-	10/11/2013
23496	Me too, for the reread. Is there anything to differentiate Stendra from the inc	tom pope	-	10/11/2013
23495	Had to go back and re-read it...(:>) ! Anybody have a guess on the royalty r	fred hayes	-	10/11/2013

Go to reply# or date (mm/dd/yy):